試す 金 - 無料
Medical Device Classification and FDA Approval: What Startups Need to Know
BioSpectrum Asia
|BioSpectrum Asia May 2025
For many innovators, the United States represents a key market, being the world's largest for medical devices. However, entering the US market requires navigating the US Food and Drug Administration's (FDA) stringent regulatory landscape, where accurate device classification is crucial. To assist innovators, the Regulatory Information and Facilitation Center (RIFC) at Venture Center, Pune has released a whitepaper early this year that offers practical insights, featuring examples of devices developed by Venture Center-supported startups to illustrate how medical devices are categorised based on risk.
 
 Under the FDA, the Center for Devices and Radiological Health (CDRH) oversees the regulation of medical devices. It ensures that patients and healthcare providers have timely and sustained access to safe, effective, and high-quality medical devices, including radiation-emitting products.
To assist innovators, the Regulatory Information and Facilitation Center (RIFC) at Venture Center has released a whitepaper titled "Classification of Medical Devices in the US", providing a simplified step-by-step guide in the form of a flowchart on determining device classification (Class I, II, III), regulatory pathways (510(k), De Novo, PMA), and key compliance requirements with examples. The whitepaper also offers practical insights, featuring examples of devices developed by Venture Center-supported startups to illustrate how medical devices are categorised based on risk.
Determining whether a product qualifies as a medical device and identifying its risk classification become important when navigating the FDA approval process. A product is classified as a medical device only if it meets the FDA's definition, which can be ambiguous and often requires further evaluation. This is because medical devices may closely resemble drugs, combination products, or wellness products, each following distinct regulatory pathways. Accurately classifying a device is crucial as it determines the level of regulatory scrutiny and the appropriate market approval process.
Fallout of Misclassification
このストーリーは、BioSpectrum Asia の BioSpectrum Asia May 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
BioSpectrum Asia からのその他のストーリー
 
 BioSpectrum Asia
India signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
New Zealand to lead new gene therapy trial for muscular dystrophy
The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Scientists in Australia grow living skin in world-first
Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare
HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund
Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan
Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium
Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Korea makes smart patch that can run tests using sweat instead of blood
A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka
The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines
China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.
1 min
BioSpectrum Asia Oct 2025
Listen
Translate
Change font size

